Do you have ocular rosacea
Ocular rosacea is an inflammatory skin condition that causes acne-like bumps and the face to become red and flushed. Commonly found on the cheeks and nose, people who experience symptoms from Rosacea can experience eye problems. Those who suffer from Rosacea also have a high level of inflammation on their cheeks and nose which can affect the eyes. When the eyes are affected, Ocular Rosacea can progress from mild discomfort to possible vision loss.
How TheraLife Can Relief Ocular Rosacea Symptoms
With a complete line of natural products that promote healthy eyes, TheraLife is a leader in chronic dry eye relief. Going to the source of dry eyes, underactive tear secretion, TheraLife Eye targets the problem from the inside out. TheraLife Eye provides a natural solution to dry eye relief by promoting the production of the body’s own healing tears.
TheraLife gives the body the ability to heal itself with the ability to make tears, eliminating painful inflammation and dryness. Restore comfortable vision and end reliance on eye drops with TheraLife Eye. Some of the TheraLife products include:
TheraLife Eye Enhanced Starter Kit – With everything included to provide dry eye relief, this all-in-one kit includes: 4 bottles of TheraLife Eye Enhanced, 1 bottle of Omega-3 Fish Oil, 1 Eye Lid Cleanser, and 1 Hot Compress. Highly recommended for Ocular Rosacea sufferers.
- TheraLife Eye Starter Kit – Including everything needed to start treating chronic dry eyes related to autoimmune conditions, this starter kit includes: 4 bottles of TheraLife Eye Enhanced, 1 bottle of Omega-3 Fish Oil, 1 Eyelid Cleanser, and 1 hot Compress.
For those who suffer from Ocular Rosacea, the TheraLife Eye Enhanced Starter Kit is recommended. Don’t delay in beginning your path to healthier, pain-free eyes with TheraLife.
Call and talk to a doctor toll free 1-877-917-1989 US/Canada. International (650) 949-6080 Email inquiries to: [email protected]
Customer Stories
click link here
Causing a number of eye complications, Rosacea can be the basis for the eyes to:
- Dry
- Bloodshot
- Watery
- Experience frequent styes
- Become red and swollen
- Create blurry vision or difficulty seeing
- Become sensitive to light
- Form a crust on the eyelids and eyelashes
- Burn or sting
- Develop little pimples, called styes, in the rim of the eye or eyelid
Causes of Ocular Rosacea
Research has discovered that 85% of people with Ocular Rosacea have blocked oil glands on the edges of their eyelids (Meibomian Gland Dysfunction). If these glands become blocked, the eyes become dry, swollen, and irritated. This leads to redness and itching in the eyes and crust on the eyelashes.
Although definitely unknown, some scientists believe that tiny spider-like creatures called mites live in the hair follicles on the eyelashes and can block the glands (Blepharitis – Demodex) .
Other scientists believe that there may be a link between rosacea and the bacteria that cause infections in the digestive system. Still, other scientists believe that rosacea is caused by a problem with the body’s blood vessels. Finally, some believe that genes or the environment can play a part in developing the skin condition.
Those who are fair-skinned are more prone to develop rosacea. Some women develop rosacea during menopause. Thirteen million Americans have been diagnosed with rosacea, and half of those patients have ocular rosacea.
Complications from Ocular Rosacea
Beginning with mild discomfort and irritation, if left untreated, Ocular Rosacea can cause serious eye complications. The cornea of the eye may become damaged, resulting in the loss of vision. Treating Ocular Rosacea helps relieve symptoms in addition to preventing serious eye complications such as vision loss or blindness.
Symptom Relief for Ocular Rosacea
Seeking a firm prognosis from an ophthalmologist or dermatologist is advised. If the Rosacea is affecting the eyes, an ophthalmologist is a good place to start. Otherwise, consult with a dermatologist. If symptoms are severe, such as light sensitivity, very red eyes, or a burning sensation, it is highly important to go to an ophthalmologist quickly.
Ocular Rosacea can be treated with a simple hygiene regime. Done regularly, the symptoms usually subside and clear up quickly. In addition to any medications that a doctor may prescribe, other steps taken to help ease the discomfort and symptoms include:
- Place a hot compress over the eyes for at least 10 minutes twice a day to ease discomfort.
- Clean eye lids with a gentle cleanser, such as Avenova or Hypochlor from TheraLife. Gently rub the eyelids with the cleanser to remove any crust and clean them thoroughly. Do not wash off eye lid cleanser afterwards.
Frequently Asked Questions
What is the best treatment for ocular rosacea?
Ocular rosacea can be relieved by ocular hygiene, cleaning eyelids with eyelid cleanser like Avenova, If you also have facial rosacea, it is important to visit a dermatologist and get it under control. TheraLife also has a complete protocol for ocular rosacea recovery. Click here to learn more.
How serious is ocular rosacea?
Ocular rosacea can lead to serious complications such as cornea damage and vision loss. It is very important that you seek help from your eye doctors right away.
Is ocular rosacea an autoimmune disease?
Ocular rosacea is an autoimmune disease, which means your own body is attacking its own cells, in this case cells that are in your eyes. Ocular rosacea involve a lot of inflammation, and therefore, a treatment like TheraLife will greatly reduce inflammation and help you get ocular rosacea under control.
What is the first line treatment for ocular rosacea?
First line of treatment for ocular rosacea is warm compress and eyelid cleansing. If that does not work, your eye doctor will prescribe a steroid eye drop for a short period of time. Follow your eye doctors instructions closely to recover faster. Any questions, call TheraLife and talk to a doctor.
How do you know if you have ocular rosacea?
Symptoms of ocular rosacea are: red eyes, light sensitivity, sandy gritty feeling in the eyes, crusty eyelashes, swollen and red eyelids, development of styes and chalazion. Visit your eye doctor immediately.
Conclusion
Overall, the outlook for ocular rosacea is positive. Even though it can be uncomfortable and annoying, it is not a life-threatening disease, and it won’t cause you to lose your vision. Once you learn the best ways to manage your symptoms and avoid your triggers, you should be able to minimize how much ocular rosacea impacts your life.
References
1. Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology:a review of recent findings. J Am Acad Dermatol. 2013;69:15–26.
2.
Vieira AC, Höfling-Lima AL, Mannis MJ. Ocular rosacea-a review. Arq Bras Oftalmol. 2012;75(5):363–369. [PubMed] [Google Scholar]3. Michel JL, Cabibel F. Frequency, severity and treatment of ocular rosacea during cutaneous rosacea. Ann Dermatol Venereol. 2003;130(1):20–24.
4. Wilkin J, Dahl M, Detmar M, Drake L, Liang MH, Odom R, Powell F, National Rosacea Society Expert Committee Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50(6):907–912.
5. Eiseman AS. The ocular manifestations of atopic dermatitis and rosacea. Curr Allergy Asthma Rep. 2006;6(4):292–298. [
6. Oltz M, Check J. Rosacea and its ocular manifestations. Optometry. 2011;82(2):92–103.
7. Dahl MV. Rosacea subtypes: a treatment algorithm. Cutis. 2004;7421-27(3 Suppl):32–34.
8. Suzuki T. Meibomitis-related keratoconjunctivitis: implications and clinicalsignificance of meibomian gland inflammation. Cornea. 2012;31(Suppl 1):S41–44.
9. Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro-and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci. 2001;42(10):2283–2292.
10. Vieira AC, Mannis MJ. Ocular rosacea: common and commonly missed. J Am Acad Dermatol. 2013;69(6 Suppl 1):S36–41.
11. Määttä M, Kari O, Tervahartiala T, Peltonen S, Kari M, Saari M, Sorsa T. Tear fluid levels of MMP-8 are elevated in ocular rosacea-treatment effect of oral doxycycline. Graefes Arch Clin Exp Ophthalmol. 2006;244(8):957–962.
12. Gupta AK, Chaudhry MM. Rosacea and its management: an overview. J Eur AcadDermatol Venereol. 2005;19(3):273–285.
13. Iovieno A, Lambiase A, Micera A, Stampachiacchiere B, Sgrulletta R, Bonini S. In vivo characterization of doxycycline effects on tear metalloproteinases in patients with chronic blepharitis. Eur J Ophthalmol. 2009;19(5):708–716.
14. Monk E, Shalita A, Siegel DM. Clinical applications of non-antimicrobial tetracyclines in dermatology. Pharmacol Res. 2011;63(2):130–145.
15. Pfeffer I, Borelli C, Zierhut M, Schaller M. Treatment of ocular rosacea with 40 mg doxycycline in a slow release form. J Dtsch Dermatol Ges. 2011;9(11):904–907.
16. Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed. 2003;2(4):234–245. [
17. Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. 2009;54(3):321–338.
18. Durrani K, Zakka FR, Ahmed M, Memon M, Siddique SS, Foster CS. Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease. Surv Ophthalmol. 2011;56(6):474–510.
19. Shimazaki J, Den S, Omoto M, Satake Y, Shimmura S, Tsubota K. Prospective, randomized study of the efficacy of systemic cyclosporine in high-risk corneal transplantation. Am J Ophthalmol. 2011;152(1):33–39.
20. Utine CA, Stern M, Akpek EK. Clinical review: topical ophthalmic use of cyclosporin A. Ocul Immunol Inflamm. 2010;18(5):352–361. [
21. Bikowski JB. Rosacea: a tiered approach to therapy. Cutis. 2000;66(4 Suppl):3–6.
22. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51(3):327–341.
23. Lazaridou E, Fotiadou C, Ziakas NG, Giannopoulou C, Apalla Z, Ioannides D. Clinical and laboratory study of ocular rosacea in northern Greece. J Eur Acad Dermatol Venereol. 2011;25(12):1428–1431.
24. Bakar O, Demircay Z, Toker E, Cakir S. Ocular signs, symptoms and tear function tests of papulopustular rosacea patients receiving azithromycin. J EurAcad Dermatol Venereol. 2009;23(5):544–549.
25. Vieira AC, An HJ, Ozcan S, Kim JH, Lebrilla CB, Mannis MJ. Glycomic analysis of tear and saliva in ocular rosacea patients: the search for a biomarker. Ocul Surf. 2012;10(3):184–192
26. Ghanem VC, Mehra N, Wong S, Mannis MJ. The prevalence of ocular signs in acne rosacea: comparing patients from ophthalmology and dermatology clinics. Cornea. 2003;22(3):230–233. [
27. Yaylali V, Ozyurt C. Comparison of tear function tests and impression cytology with the ocular findings in acne rosacea. Eur J Ophthalmol. 2002;12(1):11–17.
28. Baudouin C. A new approach for better comprehension of diseases of the ocularsurface. J Fr Ophtalmol. 2007;30(3):239–246.
29. Wladis EJ, Carlson JA, Wang MS, Bhoiwala DP, Adam AP. Toll-like receptors and vascular markers in ocular rosacea. Ophthal Plast Reconstr Surg. 2013;29(4):290–293.
30. Turner K, Pflugfelder SC, Ji Z, Feuer WJ, Stern M, Reis BL. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea. 2000;19(4):492–496.
31. Perry HD, Doshi-Carnevale S, Donnenfeld ED, Solomon R, Biser SA, Bloom AH. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea. 2006;25(2):171–175.
32. Schechter BA, Katz RS, Friedman LS. Efficacy of topical cyclosporine for the treatment of ocular rosacea. Adv Ther. 2009;26(6):651–659.
33. Fallen RS, Gooderham M. Rosacea: update on management and emerging therapies. Skin Therapy Lett. 2012;17(10):1–4. [
34. Valentín S, Morales A, Sánchez JL, Rivera A. Safety and efficacy of doxycycline in the treatment of rosacea. Clin Cosmet Investig Dermatol. 2009;2:129–140. [
35. Korting HC, Schöllmann C. Tetracycline actions relevant to rosacea treatment. Skin Pharmacol Physiol. 2009;22(6):287–294. [
1.
Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology: A review of recent findings. J Am Acad Dermatol. 2013;69(Supplement 1):S15–26. [PubMed] [Google Scholar]2.
Steinhoff M, Schmelz M, Schauber J. Facial Erythema of Rosacea – Aetiology, Different Pathophysiologies and Treatment Options. Acta Derm Venereol. 2016;96:579–86. [PubMed] [Google Scholar]3.
Gallo RL, Granstein RD, Kang S, Mannis M, Steinhoff M, Tan J, Thiboutot D. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2018;78:148–55. [PubMed] [Google Scholar]4.
Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, Powell F. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46:584–7. [PubMed] [Google Scholar]5.
Gold LM, Draelos ZD. New and Emerging Treatments for Rosacea. Am J Clin Dermatol. 2015;16:457–61. [PubMed] [Google Scholar]6.
Alexis AF, Callender VD, Baldwin HE, Desai SR, Rendon MI, Taylor SC. Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: Review and clinical practice experience. J Am Acad Dermatol. 2019;80:1722–1729.e7. [PubMed] [Google Scholar]7.
Alinia H, Tuchayi SM, James SM, Cardwell LA, Nanda S, Bahrami N, Awosika O, Richardson I, Huang KE, Feldman SR. Measurement of Disease Severity in a Population of Rosacea Patients. Dermatol Clin. 2018;36:97–102. [PubMed] [Google Scholar]8.
Patiño-Ramírez BE, Rodríguez-García A, Díaz JC, Perfecto Ávalos Y. Alteraciones de la superficie ocular en pacientes con rosácea ocular. Rev Mex Oftalmol. 2012;86:86–96. [Google Scholar]9.
Vieira AC, Mannis MJ. Ocular rosacea: common and commonly missed. J Am Acad Dermatol. 2013;69(Suppl 1):S36–41. [PubMed] [Google Scholar]11.
López-Valverde G, Garcia-Martin E, Larrosa-Povés JM, Polo-Llorens V, Pablo-Júlvez LE. Therapeutical Management for Ocular Rosacea. Case Rep Ophthalmol. 2016;7:237–42. [PMC free article] [PubMed] [Google Scholar]12.
Oltz M, Check J. Rosacea and its ocular manifestations. Optometry. 2011;82:92–103. [PubMed] [Google Scholar]14.
Rodriguez-Garcia A. Ocular Rosacea: Recent Advances in Pathogenesis and Therapy. In 2015. p. 175–199. [Google Scholar]15.
Aldrich N, Gerstenblith M, Fu P, Tuttle MS, Varma P, Gotow E, Cooper KD, Mann M, Popkin DL. Genetic vs Environmental Factors That Correlate With Rosacea: A Cohort-Based Survey of Twins. JAMA Dermatol. 2015;151:1213–9. [PubMed] [Google Scholar]17.
Steinhoff M, Buddenkotte J, Aubert J, Sulk M, Novak P, Schwab VD, Mess C, Cevikbas F, Rivier M, Carlavan I, Déret S, Rosignoli C, Metze D, Luger TA, Voegel JJ. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15:2–11. [PMC free article] [PubMed] [Google Scholar]18.
Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol. 2010;10:210–5. [PubMed] [Google Scholar]19.
Yamasaki K, Kanada K, Macleod DT, Borkowski AW, Morizane S, Nakatsuji T, Cogen AL, Gallo RL. TLR2 Expression Is Increased in Rosacea and Stimulates Enhanced Serine Protease Production by Keratinocytes. J Invest Dermatol. 2011;131:688–97. [PMC free article] [PubMed] [Google Scholar]20.
Holmes AD, Steinhoff M. Integrative concepts of rosacea pathophysiology, clinical presentation and new therapeutics. Exp Dermatol. 2017;26:659–67. [PubMed] [Google Scholar]21.
Moura AKA, Guedes F, Rivitti-Machado MC, Sotto MN. Inate immunity in rosacea. Langerhans cells, plasmacytoid dentritic cells, Toll-like receptors and inducible oxide nitric synthase (iNOS) expression in skin specimens: case-control study. Arch Dermatol Res. 2018;310:139–46. [PubMed] [Google Scholar]22.
Brown TT, Choi E-YK, Thomas DG, Hristov AC, Chan MP. Comparative analysis of rosacea and cutaneous lupus erythematosus: Histopathologic features, T-cell subsets, and plasmacytoid dendritic cells. J Am Acad Dermatol. 2014;71:100–7. [PubMed] [Google Scholar]23.
Buhl T, Sulk M, Nowak P, Buddenkotte J, McDonald I, Aubert J, Carlavan I, Déret S, Reiniche P, Rivier M, Voegel JJ, Steinhoff M. Molecular and Morphological Characterization of Inflammatory Infiltrate in Rosacea Reveals Activation of Th1/Th17 Pathways. J Invest Dermatol. 2015;135:2198–208. [PubMed] [Google Scholar]24.
Smith JR, Lanier VB, Braziel RM, Falkenhagen KM, White C, Rosenbaum JT. Expression of vascular endothelial growth factor and its receptors in rosacea. Br J Ophthalmol. 2007;91:226–9. [PMC free article] [PubMed] [Google Scholar]25.
Sulk M, Seeliger S, Aubert J, Schwab VD, Cevikbas F, Rivier M, Nowak P, Voegel JJ, Buddenkotte J, Steinhoff M. Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea. J Invest Dermatol. 2012;132:1253–62. [PMC free article] [PubMed] [Google Scholar]26.
Ghanem VC, Mehra N, Wong S, Mannis MJ. The Prevalence of Ocular Signs in Acne Rosacea: Comparing Patients From Ophthalmology and Dermatology Clinics. Cornea. 2003;22:230–3. [PubMed] [Google Scholar]27.
Gökçınar NB, Karabulut AA, Onaran Z, Yumuşak E, Budak Yıldıran FA. Elevated Tear Human Neutrophil Peptides 1–3, Human Beta Defensin-2 Levels and Conjunctival Cathelicidin LL-37 Gene Expression in Ocular Rosacea. Ocul Immunol Inflamm. 2019;27:1174–83. [PubMed] [Google Scholar]28.
Wladis EJ, Carlson JA, Wang MS, Bhoiwala DP, Adam AP. Toll-like receptors and vascular markers in ocular rosacea. Ophthal Plast Reconstr Surg. 2013;29:290–3. [PubMed] [Google Scholar]29.
Randon M, Liang H, El Hamdaoui M, Tahiri R, Batellier L, Denoyer A, Labbé A, Baudouin C. In vivo confocal microscopy as a novel and reliable tool for the diagnosis of Demodex eyelid infestation. Br J Ophthalmol. 2015;99:336–41. [PubMed] [Google Scholar] 
